Montelukast Ametas (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Ametas, is a leukotriene receptor antagonist presented as an oral dosage form for systemic use. It is employed to control asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelukast Ametas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is a leukotriene receptor antagonist used to manage conditions involving airway inflammation.

- Asthma: helps prevent chronic symptoms and reduces the frequency of exacerbations. - Allergic rhinitis: relieves nasal congestion, sneezing and itchy eyes caused by seasonal or perennial allergens. - Exercise‑induced bronchoconstriction: reduces airway narrowing that occurs during or after physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Nausea: transient gastrointestinal upset. - Cough: non‑productive. - Dizziness: brief episodes. - Fatigue: mild tiredness.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Angioedema: swelling of face, lips or throat. - Eosinophilic granulomatosis with polyangiitis: rare vasculitic condition. - Mood changes or suicidal thoughts: monitor mental health. - Hepatic injury: elevated liver enzymes. - Severe hypersensitivity: anaphylaxis or systemic rash.

Before initiating therapy, consider the following safety measures.

- Monitor liver function: assess baseline enzymes and repeat if clinically indicated. - Caution in psychiatric history: observe for mood alterations or suicidal ideation. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Adjust in renal impairment: use with caution in severe kidney disease. - Use during pregnancy only if benefit outweighs risk: discuss with prescriber. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Montelukast may interact with other medicines; awareness of the interaction level helps guide management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase montelukast plasma concentrations. - Phenobarbital, carbamazepine, rifampin: potent enzyme inducers that can reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - Warfarin: monitor INR as montelukast may affect anticoagulation stability. - Beta‑agonists (e.g., albuterol): additive bronchodilator effect may increase heart rate. - SSRIs or other antidepressants: observe for enhanced mood‑related side effects.